• Senate rules referee weakens Dem drug plan in economic bill

    6 days ago - By Star Tribune

    The Senate parliamentarian on Saturday dealt a blow to Democrats' plan for curbing drug prices but left the rest of their sprawling economic bill largely intact as party leaders prepared for first votes on a package containing many of President Joe Biden's top domestic goals.
    Read more ...

     

  • Dems lose key piece of health agenda in spending bill

    Dems lose key piece of health agenda in spending bill

    6 days ago - By Politico

    Democrats' plan to control drug prices for 180 million Americans with private health insurance has suffered yet another setback.
    The Senate parliamentarian ruled Saturday that a core piece of the party's plan can't pass the chamber with fewer than 60 votes, following arguments from both parties last week.
    Albeit a blow to the majority party, which had hoped to campaign this fall on lowering drug prices for all Americans, the nonpartisan parliamentarian's vetting means the core of the plan Democrats are trying to steer past the GOP filibuster is finally cleared for floor debate, more than a...
    Read more ...

     

  • Senate rule keeper OKs most of Democrats' energy and drug pricing provisions

    6 days ago - By ABC News

    Senate parliamentarian gives green light to most of Democrats' drug pricing plan as part of the Inflation Reduction Act.
    Read more ...

     

  • Senate Parliamentarian OKs Most Of Dems' Drug Price Controls

    Senate Parliamentarian OKs Most Of Dems' Drug Price Controls

    7 days ago - By The Huffington Post

    Democrats say the Senate parliamentarian has narrowed the party's plan for curbing drug prices but left it largely unscathed.
    Read more ...

     

  • Senate parliamentarian OKs most of Dems' drug price controls

    7 days ago - By My Sanantonio

    WASHINGTON - The Senate parliamentarian narrowed Democrats' plan for curbing drug prices but left it largely unscathed Saturday, Democrats said, as party leaders prepared to start moving their sprawling economic bill through the chamber.
    Elizabeth MacDonough, the chamber's rules arbiter, said provisions must be removed that would force drugmakers to pay rebates if their prices rise above inflation for products they sell to private insurers.
    But pharmaceutical companies would have to pay those penalties if their prices for drugs bought by Medicare rise too high.
    Other parts of the...
    Read more ...